



Extended Data Fig. 1



Extended Data Fig. 1. ELISA array results of 36 cytokines/IFNs with the HCWs' and patients' plasma. Plasma levels of cytokines and IFNs in 44 HCW controls (M : F = 15 : 29) and 38 patients in Cohort A (M : F = 17 : 21) are shown. Data are mean \pm SEM. Bonferroni's multiple comparison test was used for the comparison between M_Pt vs F_Pt, M_HCW vs F_HCW, M_HCW vs M_Pt, and F_HCW vs F_Pt. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$. All p -values < 0.10 are shown.

Extended Data Fig. 2



Extended Data Fig. 2. ELISA array results of 35 chemokines and growth factors with the HCWs' and patients' plasma. Plasma levels of chemokines and growth factors in 44 HCW controls (M : F = 15 : 29) and 38 patients in Cohort A (M : F = 17 : 21) are shown. Bonferroni's multiple comparison test was used for the comparison between M_Pt vs F_Pt, M_HCW vs F_HCW, M_HCW vs M_Pt, and F_HCW vs F_Pt. Data are mean \pm SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. All p-values < 0.10 are shown.


Extended Data Table 1. Demographic and clinical characteristics of Cohort B and healthcare worker comparison groups

	Patients (N = 93)		Healthcare Workers (N = 103)¹	
	Female – N (%)	Male – N (%)	Female – N (%)	Male – N (%)
Total	48 (51.6)	45 (48.4)	78 (75.7)	25 (24.3)
Ethnicity²				
Black/African American	16 (34.0)	10 (22.2)		
White	24 (51.1)	26 (57.8)		
Hispanic	6 (12.8)	8 (17.8)		
Other	0 (0.0)	0 (0.0)		
BMI²				
< 18	2 (4.3)	0 (0.0)	2 (2.6)	0 (0.0)
18 – 24.9	8 (17.0)	7 (15.6)	39 (50.7)	5 (21.7)
25 – 29.9	10 (21.3)	17 (37.8)	19 (24.7)	12 (52.2)
30 – 34.9	17 (36.2)	11 (24.4)	8 (10.4)	1 (4.4)
35 +	10 (21.3)	10 (22.2)	9 (11.7)	5 (21.7)
COVID Risk Factors³				
Recent cancer treatment	3 (6.3)	4 (8.9)		
Chronic heart disease	9 (18.8)	11 (24.4)		
Hypertension	20 (41.7)	25 (55.6)		
Chronic lung disease	16 (33.3)	6 (13.3)		
Immunosuppression	4 (8.3)	1 (2.2)		
Received Tocilizumab	30 (62.5)	32 (66.7)		
Received Corticosteroids	8 (16.7)	7 (14.6)		
Admitted to the ICU	12 (25.0)	11 (22.9)		
Number of samples				
1	48 (100.0)	45 (100.0)	78 (100.0)	25 (100.0)
2	28 (58.3)	26 (58.8)	8 ()	1 ()
3	11 (22.9)	7 (15.6)	0 (0.0)	0 (0.0)
4	5 (10.4)	4 (8.9)	0 (0.0)	0 (0.0)
5	2 (4.2)	0 (0.0)	0 (0.0)	0 (0.0)
6	2 (4.2)	0 (0.0)	0 (0.0)	0 (0.0)
7	1 (2.1)	0 (0.0)	0 (0.0)	0 (0.0)
8	1 (2.1)	0 (0.0)	0 (0.0)	0 (0.0)
Age – mean (SD)	61.8 (16.4)	60.0 (16.0)	36.4 (11.4)	42.0 (13.0)
Days from symptom onset – mean (SD)	11.1 (7.0)	11.9 (7.3)		

Clinical Score – mean (SD)

2.5 (1.4)

2.8 (1.3)



¹Gray areas indicate not applicable or no data available

²Cells may not sum to total due to missing data

³Categories not mutually exclusive

Extended Data Table 2. Demographic and clinical characteristics of Cohort A and healthcare worker comparison groups

	Cohort A (N = 39)		Healthcare Workers ELISA (N = 44)		Healthcare Workers Flow cytometry (N = 50)	
	Female - N (%)	Male – N (%)	Female – N (%)	Male – N (%)	Female – N (%)	Male – N (%)
Total	22 (56.4)	17 (43.4)	29 (65.9)	15 (34.1)	44 (88.0)	6 (12.0)
Ethnicity²						
Black/African American	4 (18.2)	5 (29.4)				
White	14 (63.6)	9 (52.9)				
Hispanic	4 (18.2)	2 (11.8)				
Other	0 (0.0)	0 (0.0)				
BMI²						
< 18	1 (4.6)	0 (0.0)	0 (0.0)	0 (0.0)	2 (4.5)	0 (0.0)
18 – 24.9	6 (27.3)	4 (23.5)	17 (58.6)	2 (13.3)	17 (38.6)	3 (50.0)
25 – 29.9	5 (22.7)	7 (41.2)	6 (20.7)	7 (46.7)	12 (27.3)	1 (16.7)
30 – 34.9	8 (36.4)	3 (17.7)	0 (0.0)	1 (6.7)	6 (13.6)	0 (0.0)
35 +	2 (9.1)	3 (17.7)	4 (13.8)	4 (26.7)	6 (13.6)	2 (33.3)
COVID Risk Factors³						
Recent cancer treatment	3 (13.6)	1 (5.9)				
Chronic heart disease	3 (13.6)	7 (41.2)				
Hypertension	7 (31.8)	10 (58.8)				
Chronic lung disease	4 (18.2)	4 (23.5)				
Immunosuppression	3 (13.6)	1 (5.9)				
Age – mean (SD)	60.2 (16.6)	59.2 (17.8)	41.3 (13.5)	47.5 (10.8)	36.8 (11.0)	29.0 (7.6)
Days from symptom onset – mean (SD)	12.3 (9.0)	9.2 (5.5)				
Clinical Score – mean (SD)	1.27 (0.46)	1.47 (0.62)				
On Hydroxychloroquine⁴	18 (81.8)	11 (64.7)				
On Remdesivir⁴	2 (9.1)	1 (5.9)				

¹Gray areas indicate not applicable or no data available

²Cells may not sum to total due to missing data

³Categories not mutually exclusive

⁴Status at the first sample collection

Extended Data Table 3. Thirty-nine Cohort A Patient background and sample information

ID	Sex	Age (Range)	Ethnicity	BMI	DFSO²	C₁³	C_{max}⁴	Available data type⁵
Pt01	F	40s	White	35.0	17	1	1	N, S, E, F
Pt02	F	40s	White	19.5	14	1	1	E, F
Pt03	F	50s	Black/African American	30.1	5	2	3	N, S, G, M, E, F
Pt04	F	50s	Black/African American	30.3	7	1	3	N, G, M, E, F
Pt05	F	60s	White	23.9	7	1	1	N, G, M, E, F
Pt06	F	70s	Black/African American	20.2	10	1	3	N, S, G, M, E, F
Pt07	F	40s	Hispanic	33.3	34	1	1	N, S, G, M, E, F
Pt08	F	20s	White	33.5	20	1	1	N, S, G, M, E, F
Pt09	F	60s	White	26.6	3	2	3	N, S, G, M, E, F
Pt10	F	60s	White	21.6	9	1	1	S, G, M, E, F
Pt11	F	50s	White	27.1	12	2	1	N, S, G, M, E, F
Pt12	F	80s	Hispanic	21.7	5	1	1	E, F
Pt13	F	90s	White	18.5	3	2	1	N, G, M, E, F
Pt14	F	60s	White	47.2	1	2	3	N, G, M, E, F
Pt15	F	70s	White	28.6	6	1	1	N, S, G, M, E, F
Pt16	F	80s	White	27.1	15	1	1	S, G, M, F
Pt17	F	70s	White	31.8	13	1	1	N, G, M, E, F
Pt18	F	80s	Black/African American	33.6	12	1	1	N, G, M, E, F
Pt19	F	30s	White	34.7	3	1	1	G, M, E, F
Pt20	F	50s	White	24.1	17	1	1	G, M, E, F
Pt21	F	70s	Hispanic	35.2	10	2	3	G, M, E, F
Pt22	F	50s	Hispanic	25.2	27	1	1	G, M, E, F
Pt23	M	60s	White	27.9	21	1	1	N, S, G, M, E, F
Pt24	M	40s	White	25.6	10	1	1	N, S, E, F

Pt25	M	50s	White	31.5	15	1	1	E, F
Pt26	M	60s	Black/African American	31.0	7	1	3	N, S, G, M, E, F
Pt27	M	80s	White	35.6	22	2	3	N, G, M, E, F
Pt28	M	60s	Unknown/Unavailable	25.3	11	2	3	N, S, E, F
Pt29	M	60s	White	35.5	9	2	1	N, S, G, M, E, F
Pt30	M	70s	White	24.6	3	1	1	N, S, G, M, E, F
Pt31	M	80s	Black/African American	35.2	23	3*	5	N, S, G, M, E, F
Pt32	M	90s	White	29.8	9	2	3	N, G, M, E, F
Pt33	M	80s	Black/African American	47.3	8	1	4	G, M, E, F
Pt34	M	20s	Black/African American	29.5	8	2	1	G, M, E, F
Pt35	M	30s	Black/African American	28.0	4	1	1	N, G, M, E, F
Pt36	M	50s	Hispanic	22.1	7	1	1	N, S, G, M, E, F
Pt37	M	40s	Hispanic	19.3	7	1	1	N, G, M, E, F
Pt38	M	80s	White	23.3	4	2	1	N, G, M, E, F
Pt39	M	50s	White	26.4	6	1	1	N, S, G, M, E, F

1. Days from symptom onset at the first sample collection

2. C_1 : Clinical score at the first sample collection date

3. C_{max} : Maximum clinical score during the admission later than the first sample collection date

4. Collected sample/data types at the first sample collection date. N; Nasopharyngeal viral load, S; Saliva viral load, G; Plasma anti-S1-IgG, M; Plasma anti-S1-IgM, E; Plasma ELISA, F; PBMC flow cytometry

*In Pt31, Toci was started on the day of the first sample collection.

Extended Data Table 4. Adjusted least square means difference over time in immune response between male and female COVID-19 patients¹ in Cohort B. Sample numbers (N) used for each assay and analysis are summarized below the table.

	Female vs. Male Patients	
	Difference (95% CI)	p-value
Viral Load²		
Nasopharyngeal	-0.50 (-0.58, 1.57)	0.37
Saliva	-0.73 (-0.35, 1.80)	0.18
Antibody³		
Anti-S1IgG	0.04 (-0.25, 0.33)	0.80
Anti-S1IgM	0.02 (-0.17, 0.21)	0.86
Interferon Response⁴		
IFN α 2	0.25 (0.02, 0.49)	0.03
IFN γ	0.14 (-0.14, 0.41)	0.32
IFN λ 2	-0.06 (-0.43, 0.31)	0.74
Cytokines, Chemokines and Growth Factors⁴		
IL-1 β	0.05 (-0.24, 0.34)	0.73
IL-1RA	-0.09 (-0.38, 0.19)	0.51
IL-18	-0.05 (-0.28, 0.18)	0.66
IL-6	-0.04 (-0.38, 0.30)	0.81
IL-8	-0.05 (-0.26, 0.17)	0.66
CXCL10	-0.23 (-0.55, 0.09)	0.16
CCL2	-0.07 (-0.16, 0.03)	0.18
CCL5	-0.14 (-0.24, -0.04)	0.008
M-CSF	-0.02 (-0.34, 0.30)	0.90
CCL4	-0.10 (-0.21, 0.01)	0.08
TNFSF10	0.04 (-0.11, 0.19)	0.61
G-CSF	-0.14 (-0.52, 0.24)	0.46
PBMC Composition⁵		
T Cells	5.49 (-1.45, 12.43)	0.12
B Cells	-1.09 (-2.74, 0.57)	0.20
cMono	-1.01 (-2.97, 0.94)	0.31
intMono	0.56 (-0.59, 1.70)	0.34
ncMono	-1.80 (-6.00, 2.39)	0.40
T Cell Phenotypes⁶		
CD4	0.71 (-6.12, 7.54)	0.84
CD8	3.10 (-2.01, 8.20)	0.23
CD38+HLA-DR+CD4	-0.19 (-0.78, 0.40)	0.52
CD38+HLA-DR+CD8	0.67 (-0.37, 1.71)	0.21
PD-1+TIM-3+CD4	0.18 (-0.18, 0.54)	0.33
PD-1+TIM-3+CD8	0.30 (-0.25, 0.85)	0.29

¹Adjusted for age, days from symptom onset, Toci treatment, CS treatment and ICU status

²Log₁₀(SARS-CoV-2 copies/mL). N_{plod}: N_{F_Pt} = 27, N_{M_Pt} = 25. Sload: N_{F_Pt} = 16, N_{M_Pt} = 14.

³OD450. N_{F_Pt} = 41, N_{M_Pt} = 37.

⁴Log₁₀ pg/mL. N_{F_Pt} = 43, N_{M_Pt} = 38.

⁵As percent of live cells. N_{F_Pt} = 42, N_{M_Pt} = 36.

⁶As percent of CD3-positive cells. N_{F_Pt} = 42, N_{M_Pt} = 36.

Extended Data Table 5. Adjusted least square means difference over time in immune response between male and female COVID-19 patients in the Cohort B and male and female healthcare workers.¹
Sample numbers (N) used for each assay and analysis are summarized below the table.

	Female Patients vs. Female Healthcare Workers		Male Patients vs. Male Healthcare Workers		Difference-in-Differences	
	Difference (95% CI)	p-value	Difference (95% CI)	p-value	Difference (95% CI)	p-value
Antibody²						
Anti-S1IgG	1.00 (0.70, 1.30)	<0.001	0.99 (0.73, 1.25)	<0.001	0.01 (-0.29, 0.31)	0.96
Anti-S1IgM	0.72 (0.47, 0.96)	<0.001	0.72 (0.45, 0.98)	<0.001	0.001 (-0.22, 0.22)	0.99
Interferon Response³						
IFN α 2	0.54 (0.25, 0.83)	<0.001	0.17 (-0.15, 0.49)	0.29	0.36 (-0.003, 0.73)	0.05
IFN γ	0.61 (0.24, 0.99)	0.002	0.34 (-0.20, 0.89)	0.22	0.27 (-0.37, 0.91)	0.41
IFN λ 2	-0.19 (-0.68, 0.30)	0.44	-0.47 (-1.02, 0.08)	0.09	0.28 (-0.35, 0.90)	0.38
Cytokines, Chemokines and Growth Factors³						
IL-1 β	0.24 (-0.13, 0.61)	0.21	0.26 (-0.27, 0.80)	0.33	-0.03 (-0.60, 0.66)	0.93
IL-1RA	0.82 (0.56, 1.08)	<0.001	0.71 (0.41, 1.02)	<0.001	0.11 (-0.27, 0.50)	0.57
IL-18	0.44 (0.09, 0.80)	0.02	0.39 (0.08, 0.69)	0.01	0.05 (-0.27, 0.38)	0.75
IL-6	1.85 (1.41, 2.30)	<0.001	2.08 (1.69, 2.46)	<0.001	-0.22 (-0.75, 0.30)	0.40
IL-8	0.77 (0.52, 1.02)	<0.001	1.00 (0.77, 1.23)	<0.001	-0.23 (-0.55, 0.09)	0.16
CXCL10	1.06 (0.72, 1.41)	<0.001	1.45 (1.18, 1.71)	<0.001	-0.38 (-0.77, 0.003)	0.05
CCL2	0.12 (0.03, 0.21)	0.01	0.15 (0.03, 0.27)	0.02	-0.03 (-0.16, 0.10)	0.68
CCL5	0.08 (-0.03, 0.19)	0.15	0.26 (0.17, 0.35)	<0.001	-0.18 (-0.30, -0.05)	0.003
M-CSF	0.70 (0.29, 1.11)	<0.001	1.06 (0.47, 1.65)	<0.001	-0.36 (-1.04, 0.32)	0.30
CCL4	0.15 (0.02, 0.28)	0.03	0.27 (0.17, 0.38)	<0.001	-0.13 (-0.27, 0.02)	0.09
TNFSF10	0.11 (-0.07, 0.29)	0.22	0.05 (-0.15, 0.24)	0.65	0.07 (-0.18, 0.31)	0.60
G-CSF	0.79 (0.33, 1.24)	<0.001	0.51 (-0.19, 1.20)	0.15	0.28 (-0.51, 1.07)	0.49
PBMC Composition⁵						
T Cells	-19.06 (-10.08, 28.04)	<0.001	-24.57 (-33.68, -15.47)	<0.001	5.52 (-3.41, 14.44)	0.22

B Cells	3.56 (2.00, 5.11)	<0.001	5.31 (3.16, 7.45)	<0.001	-1.75 (-3.78, 0.03)	0.09
cMono	2.73 (0.51, 4.95)	0.02	3.59 (0.85, 6.33)	0.01	-0.86 (-3.50, 1.78)	0.52
intMono	2.42 (0.97, 3.86)	0.001	2.06 (0.74, 3.38)	0.002	0.36 (-1.03, 1.75)	0.61
ncMono	3.31 (-1.69, 8.32)	0.19	5.61 (0.87, 10.35)	0.02	-2.30 (-6.23, 1.63)	0.25
T Cell Phenotypes ⁶						
CD4	-1.54 (-7.26, 4.19)	0.60	2.31 (-8.02, 12.64)	0.66	-3.85 (-14.92, 7.23)	0.50
CD8	3.47 (-1.41, 8.36)	0.16	1.11 (-5.14, 6.62)	0.81	2.37 (-4.22, 8.95)	0.48
CD38+HLA-DR+CD4	0.95 (0.50, 1.41)	<0.001	0.98 (0.43, 1.53)	<0.001	-0.02 (-0.65, 0.60)	0.94
CD38+HLA-DR+CD8	2.18 (0.92, 3.44)	0.001	1.83 (0.78, 2.88)	<0.001	0.35 (-0.61, 1.32)	0.47
PD-1+TIM-3+CD4	0.83 (0.38, 1.28)	<0.001	0.74 (0.23, 1.25)	0.01	0.09 (-0.35, 0.54)	0.68
PD-1+TIM-3+CD8	1.23 (0.65, 1.81)	<0.001	1.01 (0.42, 1.60)	<0.001	0.22 (-0.38, 0.81)	0.57

¹Adjusted for age

²OD450. N_{F_Pt} = 42, N_{F_HCW} = 74, N_{M_Pt} = 39, N_{M_HCW} = 13 (IgG), 4 (IgM).

³Log₁₀ pg/mL. N_{F_Pt} = 44, N_{F_HCW} = 43, N_{M_Pt} = 41, N_{M_HCW} = 15.

⁴As percent of live cells. N_{F_Pt} = 42, N_{F_HCW} = 29, N_{M_Pt} = 39, N_{M_HCW} = 6.

⁵As percent of CD3-positive cells. N_{F_Pt} = 42, N_{F_HCW} = 43, N_{M_Pt} = 39, N_{M_HCW} = 6.

Extended Data Table 6. Age-Adjusted least square means difference in baseline immune response between male and female Cohort A patients with deteriorated versus stabilized disease course¹

	Female Deteriorated (n=6) vs. Female Stabilized (n=16)		Male Deteriorated (n=6) vs. Male Stabilized (n=11)		Difference-in-Differences	
	Difference (95% CI)	p-value	Difference (95% CI)	p-value	Difference (95% CI)	p-value
PBMC Composition						
CD38+HLA-DR+CD4 ³	0.82 (-0.92, 2.56)	0.58	-0.34 (-2.54, 1.85)	0.97	1.16 (-0.93, 3.25)	0.27
CD38+HLA-DR+CD8 ³	-0.07 (-2.46, 2.32)	0.99	-0.93 (-3.95, 2.10)	0.84	0.86 (-3.73, 2.02)	0.55
PD-1+TIM-3+CD4 ³	0.64 (-0.55, 1.84)	0.48	-0.39 (-1.89, 1.13)	0.90	1.02 (-0.41, 2.46)	0.16
PD-1+TIM-3+CD8 ³	-0.44 (-2.25, 1.37)	0.91	-0.43 (-2.72, 1.85)	0.96	-0.01 (-2.19, 2.17)	0.99
IFN γ +CD8 ³	3.45 (-1.61, 8.51)	0.27	-3.83 (-10.29, 2.63)	0.39	7.28 (1.15, 13.40)	0.02
Cytokines, Chemokines and Growth Factors⁴						
IL-8	-0.07 (-0.78, 0.64)	0.99	-0.36 (-1.24, 0.52)	0.69	0.29 (-0.54, 1.16)	0.49
IL-18	0.27 (-0.16, 0.70)	0.34	0.21 (-0.32, 0.74)	0.71	0.06 (-0.44, 0.56)	0.81
CXCL10	1.11 (0.12, 2.10)	0.02	0.10 (-1.13, 1.32)	0.99	1.02 (-0.14, 2.17)	0.08
sCD40L	-0.51 (-0.95, -0.07)	0.01	-0.64 (-1.18, -0.09)	0.02	0.12 (-0.39, 0.64)	0.62
CCL5	0.19 (-0.17, 0.55)	0.50	0.27 (-0.18, 0.72)	0.39	-0.08 (-0.50, 0.35)	0.71
TNFSF10	0.36 (-0.04, 0.75)	0.09	-0.23 (-0.72, 0.26)	0.58	0.59 (0.13, 1.04)	0.01
M-CSF	0.71 (-0.19, 1.62)	0.16	0.15 (-0.98, 1.27)	0.98	0.57 (-0.49, 1.62)	0.28
IL-15	0.47 (-0.18, 1.12)	0.22	-0.26 (-1.06, 0.54)	0.81	0.73 (-0.02, 1.48)	0.06

¹Adjusted for age

²As percent of live cells

³As percent of CD3-positive cells

⁴Log₁₀ pg/mL

Extended Data Table 7. Markers used for the identification of cell subsets in flow cytometry analyses.

PBMC/Single Cells/Single Cells/Live...	Live singlet gate
.../CD19+CD3-	B cells
.../CD19-CD3+	T cells
.../CD19-CD3+/CD3+CD56+	NKT cells
.../CD19-CD3-/CD56+CD66b-	NK cells
.../CD19-CD3-/CD56-CD66b-/CD14+CD16-	Classical Monocytes (cMono)
.../CD19-CD3-/CD56-CD66b-/CD14+CD16var	Intermediate Monocytes (intMono)
.../CD19-CD3-/CD56-CD66b-/CD14-CD16+	Non-Classical Monocytes (ncMono)
.../CD19-CD3-/CD56-CD66b-/CD14-CD16-/CD304+	Plasmacytoid DCs (pDC)
.../CD19-CD3-/CD56-CD66b-/CD14-CD16-/CD304-/CD11b+	Macrophages
.../CD19-CD3-/CD56-CD66b-/CD14-CD16-/CD304-/CD141+HLA-DR+	cDC1
.../CD19-CD3-/CD56-CD66b-/CD14-CD16-/CD304-/CD1c+HLA-DR+	cDC2
.../CD3+/CD8+CD4-	CD8 T cells
.../CD3+/CD8+CD4-/CD3+CD45RA+/CD127+CCR7+/CD3+PD1-	Naïve CD8T
.../CD3+/CD8+CD4-/CD3+CD45RA+/CD127-CCR7-	CD8Temra
.../CD3+/CD8+CD4-/CD3+CD45RA-/CD127+CCR7+	Central Memory CD8T (CD8Tcm)
.../CD3+/CD8+CD4-/CD3+CD45RA-/CD127+CCR7-	Effector Memory CD8T (CD8Tem)
.../CD3+/CD8+CD4-/CD3+CD45RA-/TIM3+PD1+	PD-1+TIM-3+CD8 (terminally differentiated CD8)
.../CD3+/CD8+CD4-/CD3+CD45RA-/CXCR5+PD1+	Follicular CD8T (FollicCD8)
.../CD3+/CD8+CD4-/CD38+HLA-DR+	CD38+HLA-DR+CD8 (TCR-activated CD8)
.../CD3+/CD8+CD4-/GranzymeB+	Granzyme B-expressing CD8T (CD8GzB)
.../CD3+/CD8+CD4-/IFN γ +	IFN γ - expressing CD8T (IFN γ +CD8)
.../CD3+/CD8+CD4-/TNF α +	TNF α -expressing CD8T (TNF α CD8)
.../CD3+/CD8+CD4-/IL2+	IL2- expressing CD8T (IL2+CD8)
.../CD3+/CD8+CD4-/IL6+	IL6-expressing CD8T (IL6+CD8)
.../CD3+/CD8+CD4-/CXCR3+	CXCR3-expressing CD8T (CXCR3+CD8)
.../CD3+/CD8-CD4+	CD4 T cells
.../CD3+/CD8-CD4+/CD3+CD45RA+/CD127+CCR7+/CD3+PD1-	Naïve CD4T
.../CD3+/CD8-CD4+/CD3+CD45RA+/CD127-CCR7-	CD4Temra
.../CD3+/CD8-CD4+/CD3+CD45RA+/CD127-CD25hi/CD3+HLA-DR-	Resting Natural Regulatory CD4T (CD4rnTreg)

.../CD3+/CD8-CD4+/CD3+CD45RA-/CD127+CCR7+	Central Memory CD4T (CD4Tcm)
.../CD3+/CD8-CD4+/CD3+CD45RA-/CD127+CCR7-	Effector Memory CD4T (CD4Tem)
.../CD3+/CD8-CD4+/CD3+CD45RA-/TIM3+PD1+	PD-1+TIM-3+ CD4T (terminally differentiated CD4 T cells)
CD3+/CD8-CD4+/CD3+CD45RA-/CD127-CD25hi Treg/CD3+HLA-DR+	Effector Regulatory CD4T (CD4effTreg)
CD3+/CD8-CD4+/CD3+CD45RA-/CD127-CD25hi Treg/CD3+HLA-DR-	Natural Regulatory CD4T (CD4nTreg)
.../CD3+/CD8-CD4+/CD38+HLA-DR+	CD38+HLA-DR+CD4T (TCR-activated CD4)
.../CD3+/CD8-CD4+/IFN γ +	IFN γ - expressing CD4T (IFN γ +CD4)
.../CD3+/CD8-CD4+/TNF α +	TNF α -expressing CD4T (TNF α +CD4)
.../CD3+/CD8-CD4+/IL2+	IL2- expressing CD4T (IL2+CD4)
.../CD3+/CD8-CD4+/IL6+	IL6-expressing CD4T (IL6+CD4)
.../CD3+/CD8-CD4+/IL4+	IL4-expressing CD4T (IL4+CD4)
.../CD3+/CD8-CD4+/IL17+	IL17-expressing CD4T (IL17+CD4)
.../CD3+/CD8-CD4+/CD3+CXCR3+	CXCR3-expressing CD4T (CXCR3+CD4)